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Epstein–Barr virus (EBV) is a double-stranded DNA
virus belonging to the Gammaherpesvirinae subfamily.
Epstein–Barr virus has a lifelong persistence in the
human host, where it is common and is distributed
worldwide in the normal population2 (1). The virus is
ubiquitous, with a seroprevalence of between 50 and
95% (2). After primary infection, EBV establishes a
latent infection in a small proportion of B lymphocytes
as well as in oronasopharyngeal and salivary gland epi-
thelial cells, periodically replicates in the oropharynx or
in salivary gland epithelium, and is then shed in the
saliva (3).
It is well known that EBV is associated with a variety
of malignant disorders such as nasopharyngeal carci-
noma (4), Burkitts lymphoma, Hodgkins disease, and
B-cell lymphoma (5, 6). It is frequently associated with
malignant and benign diseases of the immunocompro-
mised (e.g. diﬀerent B-cell lymphomas and oral hairy
leukoplakia) (2, 5). Besides these established disease
associations, a role of EBV has been presumed in many
diﬀerent malignant diseases, such as leiomyosarcoma,
gastric adenocarcinoma, certain non-B-cell lymphomas
(1), and oral squamous cell cancer (OSCC) (7), as well as
in some benign and potentially malignant oral lesions
and diseases, including oral lichen planus (OLP) (8),
gingivitis, and periodontitis (2).
Several viral proteins have been found be involved in
the transforming activity of, and in the carcinogenesis
induced by, EBV; these include the latency-associated
proteins latent membrane proteins 1 and 2 (LMP-1 and
LMP-2) and Epstein–Barr virus nuclear antigens
(EBNA1–6) (3, 5). Of these, LMP-1, EBNA-2, and
EBNA-3 are indispensable for the immortalization of B
cells; LMP-1 was also shown to be involved in the
transformation of murine ﬁbroblasts (3, 5). Some of
these proteins were demonstrated, by immunohisto-
chemical analyses, to be present in EBV-associated
malignant cells (5).
The prevalence of EBV in oral samples varies widely in
diﬀerent studies. Most south-east Asian studies found a
high prevalence of EBV and concluded an aetiological
role of EBV in OSCC (9, 10); and in an Egyptian pop-
ulation this was also supported by immunohistochemical
detection of LMP-1, the EBV antigen associated with
transforming activity (11, 12). By contrast, North
American studies, as well as West and North European
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We tested 65, 44, and 116 patients with oral squamous cell cancer (OSCC), oral
leukoplakia (OL), and oral lichen planus (OLP) against 68 age-matched controls for
the presence of Epstein–Barr virus (EBV). Apparently healthy mucosa was simulta-
neously sampled and examined in all patients. Paraﬃn-embedded tissue sections of all
EBV-positive patients with OSCC were examined for latent membrane protein-1
(LMP-1) expression (demonstrable in most EBV-associated malignancies) using
immunohistochemistry. The prevalence of EBV in the controls and in OSCC, OL, and
OLP lesions was 19.1%, 73.8%, 29.5%, and 46.6%, respectively, and 66.2%, 22.7%,
and 31.9% in the healthy mucosa of patients, respectively. The prevalence of EBV in
OSCC patients was signiﬁcantly higher than in controls or in respective samples of the
other two patient groups both in the lesion and in the healthy mucosa. Comparisons
including only patients with EBV-negative lesions yielded similar results. Lesions of
patients with OLP, but not of patients with OL, diﬀered signiﬁcantly from controls in
EBV prevalence. In OSCC, LMP-1 expression was not detected, and EBV carriage was
not signiﬁcantly associated with any risk factors and did not inﬂuence the outcome.
Although a high prevalence of EBV was found in OSCC, comparable carriage rates on
healthy mucosa of patients indicated that an aetiological role of EBV is unlikely.
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studies, regularly report lower prevalences of EBV and
conclude that the aetiological role of EBV is doubtful in
OSCC (13–15).
The aim of the present study was to collect data on
the prevalence of EBV DNA in patients with OSSC,
OLP, and oral leukoplakia (OL) in an eastern Hun-
garian population with a relatively high incidence of
OSCC. To track the source of EBV in these patients we
also took a sample of the apparently healthy mucosa of
the patients simultaneously when taking a sample of the
lesion.
Material and methods
Study groups, specimens, and DNA extraction
All patients enrolled in the study attended the Department
of Oral and Maxillofacial Surgery and the Department of
Periodontology, Faculty of Dentistry, University of
Debrecen, Hungary, during 2003–2007. Histopathological
results based on targeted biopsy were available at the time
of sample collection in each patient. We included OSCC
patients if (i) they were newly diagnosed patients and (ii)
they did not undergo neoadjuvant chemotherapy or
radiotherapy before the surgical intervention and specimen
collection. Similarly, we included patients with potentially
malignant oral lesions if (i) they were newly diagnosed
patients and (ii) they did not receive any therapy for their
lesion before sampling. All individuals fulﬁlling the inclu-
sion criteria and agreeing to participate were enrolled.
Sixty-ﬁve patients with OSCC (51 men, 14 women; mean
age 54.4 yr; age-range 25–80 yr), 44 patients with OL (14
men, 30 women; mean age 56.3 yr; age-range 29–91 yr),
and 116 patients with OLP (29 men, 87 women; mean age
55.0 yr; age-range 23–79) were enrolled in the study. The
age-matched control group consisted of 68 individuals
without a history of oral disease or malignancy, with a
healthy oral mucosa (16 men, 52 women; age-range
22–77 yr; mean age 52.5 yr). Control individuals were from
the same geographical area as the patients (eastern Hun-
gary) and had been referred to the Faculty of Dentistry for
regular oral screening3 . Written informed consent was
collected from each patient4 enrolled. The study was
approved by the local ethics committee (approval number:
2273–2004).
Data were also collected on exposure to known risk fac-
tors of OSCC relevant in the region (smoking, alcohol
consumption) and pathological characteristics [localization,
tumour node metastasis (TNM) stage according to the
Tumour-Node-Metastasis staging of carcinomas and histo-
logical grade of the tumour]. To assess complication-free
survival (survival without recurrence, growth of new
tumour or metastasis), patients were followed-up after sur-
gical intervention; the mean follow-up time was 31 months
(range: 1.5–60 months).
As certain clinical variants of OLP (erosive and atrophic
forms; EA-OLP) are more prone to malignant transfor-
mation than others (plaque-like and reticular forms;
non-EA-OLP), and, similarly, there are OLs with higher
(non-homogeneous OL; erythroleukoplakia and verrucous
forms) and with lower (homogeneous OL) risks of malig-
nization, potentially malignant oral lesions (OL and OLP)
were divided into two respective groups according to clinical
appearance associated with higher risk of malignant trans-
formation, to subgroups EA-OLP (59 individuals: 13 men,
46 women; mean age 57.5 yr; age-range 23–79 yr) and non-
EA-OLP (57 individuals: 16 men, 41 women; mean age
52.4 yr; age-range 24–75 yr), as well as to non-homo-
geneous OL (14 individuals: 5 men, 9 women; mean age
51.5 yr; range 29–71 yr) and homogeneous OL (30 indi-
viduals: 9 men, 21 women; mean age 58.5 yr; age-range
35–91 yr).
Excised tissue samples of patients with OSCC were
obtained, during surgical intervention, from the centre of
the tumour. Another part of the tissue sample was submit-
ted for histopathological and immunohistochemical analy-
ses (see below). In OL and OLP groups, exfoliated cells were
collected from the surface of oral lesions. In all groups of
patients, before specimen collection from the lesions, exfo-
liated cells were harvested from the apparently healthy
mucosa at the farthest possible site from the lesion. Control
specimens consisted of cytobrush-harvested exfoliated buc-
cal epithelial cells collected from healthy individuals. To
minimize contamination of the exfoliated cell samples with
saliva, sampling was preceded by two thorough mouth
rinses with physiological saline.
DNA was isolated using TRI Reagent (Sigma, St Louis,
MO, USA), according to the manufacturers recommenda-
tions for tumour tissue samples and exfoliated cells,5 from
OSCC patients. Extraction of DNA from samples of exfo-
liated cells from patients with OL and OLP, and from
control individuals, was performed with proteinase K
digestion followed by treatment with 5 M NaCl, and DNA
was precipitated using 96% ethanol.
EBV detection by polymerase chain reaction
We used a nested polymerase chain reaction (PCR),
amplifying a 97-bp region of the internal repeat of the
BamH1-W fragment of the EBV genome, constructed from
two previously described overlapping PCR assays (16).
Brieﬂy, primers EBV-F (5¢-GAGACCGAAGTGAAG
GCCCT-3¢) and EBV-R (5¢-ACAGCTCCTAAGAAGG
CACC-3¢) were used to amplify a 171-bp product, and then
primers EBV B-F (5¢-GCCAGAGGTAAGTGGACTTT-3¢)
and EBV B-R (5¢-GAGGGGACCCTGAGACGGGT-3¢)
were used to amplify a 97-bp fragment within the amp-
limer yielded by the ﬁrst round of PCR. Both PCR assays
were performed in a ﬁnal volume of 25 ll containing
250 lM of each dNTP, 25 pmol of each primer, and 0.5 U
of GoTaq DNA polymerase in 1 · PCR buﬀer containing
MgCl2 (supplied by the manufacturer; Promega, Madison,
WI, USA). Thermal proﬁles were: 94C for 5 min; 35 cycles
of 94C for 30 s, 58C for 30 s, and 72C for 30 s; and a
ﬁnal extension at 72C for 5 min in both rounds. DNA from
the EBV-positive B95-8 cell line was used as a positive
control.
Detection of LMP-1 using immunohistochemistry
Immunohistochemistry was performed with the Dako-
Cytomation LSAB+ System AP (Dako Denmark, Glost-
rup, Denmark), using monoclonal mouse antibodies
against LMP-1, according to the manufacturers recom-
mendations. Two paraﬃn-embedded tumour-tissue sections
were tested in all 48 patients with EBV-positive OSCC
tumour tissue. A paraﬃn-embedded lymph node prepara-
tion from a patient with EBV-positive Hodgkins disease
was used as a positive control, while lymph node sections
from EBV-negative Hodgkins disease patients served as
negative controls.
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Statistical analysis
Statistical comparison of prevalence data was performed
using chi-square and Fishers exact tests. Logistic regression
was used to analyze the association between EBV carriage
and patient characteristics (gender and age) as well as the
clinical appearance of OLP. Because of the small number of
patients with non-homogeneous OL6 , the clinical appearance
of OL was not analyzed statistically. The association of
tumour characteristics (localization, histological grade, and
TN7 stage) with exposure to risk factors (smoking and
alcohol consumption) in patients with OSCC was also
analyzed using logistic regression. Tumour-free survival of
OSCC patients was analyzed using the Kaplan–Meier test.
All tests were carried out with a conﬁdence interval (CI) of
95% using spss 15.0 for Windows software.
Results
EBV prevalence data
The prevalence of EBV DNA was 19.1% (13/68) in the
control group. In patients with OSCC, OL, and OLP, the
carriage rates in the lesion were 73.8% (48/65), 29.5%
(13/44), and 46.6% (54/116), respectively, and 66.2%
(43/65), 22.7% (10/44), and 31.9% (37/116) in the
apparently healthy mucosa, respectively. If patients were
divided according to the presence or absence of EBV
DNA in their lesions, prevalence rates in the apparently
healthy mucosa of patients with EBV-positive vs. EBV-
negative lesions were 34/48 (70.8%) vs. 9/17 (52.9%), 5/
13 (38.5%) vs. 5/31 (16.1%), and 29/54 (53.7%) vs. 8/62
(12.9%) for OSCC, OL, and OLP patients, respectively.
When patients with OLP were divided, the two sub-
groups showed comparable EBV prevalences, both in the
lesion (45.6%, 26/57 in non-EA-OLP; and 47.5%, 28/59
in EA-OLP) and on the healthy mucosa (33.3%, 19/57 in
non-EA-OLP; and 30.5%, 18/59 in EA-OLP).
Statistical analysis of prevalence data
The prevalence of EBV in the lesion, as well as on the
apparently healthy mucosa, of patients with OSCC, was
signiﬁcantly higher than the prevalence in the controls or
in respective samples of the other two groups of patients
(Table 1). Regarding only patients with EBV-negative
lesions, similar results were found (Table 2). However,
when regarding only patients carrying EBV DNA in the
lesions, mucosal carriage rates of patients with OSCC
and patients with OLP were not signiﬁcantly diﬀerent,
but were signiﬁcantly higher than the prevalences of EBV
in mucosal controls or in patients with OL (Table 2).
No signiﬁcant diﬀerences were detected in the preva-
lence of EBV between patients with OL and controls
(Table 1). By contrast, patients with OLP carried EBV
DNA more frequently than controls in the lesion but not
on the healthy mucosa. However, the prevalence of EBV
on the apparently healthy mucosa was found to be sig-
niﬁcantly higher in patients with EBV-positive lesions
compared with controls, but not in patients with EBV-
negative OLP lesions compared with controls (Table 2).
Comparing patients with the two potentially malig-
nant oral disorders, positivity in the lesion was signiﬁ-
cantly higher for OLP than for OL. Regarding EBV
carriage on the healthy mucosa, OLP and OL patients
never diﬀered signiﬁcantly; neither when comparing the
total patient populations, nor when examining patients
with EBV-positive or EBV-negative lesions separately
(Table 1 and Table 2). The prevalence of EBV in
Table 1
Statistical comparison of Epstein–Barr virus (EBV) prevalence data in different study groups
Lesion Apparently healthy mucosa
OLP
(n = 116)
OL
(n = 44)
OSCC
(n = 65)
OLP
(n = 116)
OL
(n = 44)
OSCC
(n = 65)
Controls (n = 68) P < 0.001 NS P < 0.001 NS NS P < 0.001
OLP (n = 116) P = 0.049 P < 0.001 NS P < 0.001
OL (n = 44) P < 0.001 P < 0.001
NS, not signiﬁcant; OL, oral leukoplakia; OLP, oral lichen planus; OSCC, oral squamous cell cancer.
Table 2
Statistical comparison of Epstein–Barr virus (EBV) prevalences in apparently healthy mucosa
Apparently healthy mucosa of EBV-positive patients Apparently healthy mucosa of EBV-negative patients
OLP (n = 54) OL (n = 13) OSCC (n = 48) OLP (n = 62) OL (n = 31) OSCC (n = 17)
Controls
(n = 68)
P < 0.001 NS P < 0.001 Controls (n = 68) NS NS P = 0.010
OLP
(n = 54)
NS NS OLP (n = 62) NS P = 0.001
OL
(n = 13)
P = 0.050 OL (n = 31) P = 0.018
NS, not signiﬁcant; OL, oral leukoplakia; OLP, oral lichen planus; OSCC, oral squamous cell cancer.
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EA-OLP and non-EA-OLP patients did not diﬀer sig-
niﬁcantly either in the lesion or on the healthy mucosa;
therefore, the two subgroups were not examined in fur-
ther comparisons.
Immunohistochemistry
The lymph node sections of the Hodgkins disease
patients (positive control) were consistently strongly
positive for EBV8 , but none of the 48 samples tested, or
the lymph nodes from EBV-negative Hodgkins disease
patients, was found to be LMP-1 positive.
Analysis of the association of EBV with
clinicopathological data
Epstein–Barr virus-positive and EBV-negative OSCC
patients did not statistically diﬀer in patient characteri-
stics (age, gender) and exposure to risk factors (smoking
and alcohol consumption) or clinical data (localization,
TN stage, and histological grade of the tumour). The
presence of EBV in the lesion or in the apparently
healthy mucosa was not found to inﬂuence survival, and
did not increase the risk of poor outcome.
In the case of patients with OL, younger age (under
55 yr), but not gender, was a risk factor associated with
EBV carriage in the lesion [odds ratio (OR) = 4.09;
CI = 1.02–16.40; P = 0.047]. In patients with OLP,
EBV infection appeared more frequently in men than in
women (OR = 2.82; CI = 1.17–6.79; P = 0.02), but
age was not signiﬁcantly associated with EBV carriage.
Epstein–Barr virus carriage did not inﬂuence the risk of
unfavourable clinical appearance (EA-OLP).
Discussion
Data on the aetiological role of EBV in OSCC is con-
troversial. Generally, studies ﬁnding a low prevalence of
EBV concluded no, or a negligible, aetiological role
(14, 17, 18); by contrast, studies reporting a relatively
high prevalence of EBV frequently supported an aetio-
logical role9 (7, 19). In some cases, immunohistochemistry
has been used to conﬁrm (11) or to reject (14) the pos-
sibility of the role of EBV in OSCC. Curiously, most
studies concluding an aetiological role of EBV in OSCC
were conducted on south-eastern Asian or North African
populations with a high prevalence of EBV-associated
nasopharyngeal carcinoma (6, 9, 10).
The prevalence of EBV in our study was high com-
pared with European studies (13) and was comparable to
data from studies supporting an aetiological role (9–12),
suggesting that EBV may have a role in OSCC in the
study population. However, we believe that the high
proportion of EBV carriers in our OSCC patients is more
likely to be a result of other factors (e.g. tumour-induced
B-lymphocyte activation and/or inﬁltration of the
tumour tissue by B cells).
Tumour tissue and apparently healthy mucosa showed
almost the same EBV prevalence rate in OSCC patients,
which is, to our knowledge, an issue as yet unexamined.
Moreover, even patients with EBV-negative tumours had
a notably high carriage rate of EBVon the healthymucosa
(signiﬁcantly higher than in the oral controls, but com-
parable to that of patients with EBV-positive tumours).
This means that although EBV DNA is present in the
majority of the OSCCs, it is prevalent to a comparable
degree also on the normal mucosa of OSCC patients.10 This
situation is completely diﬀerent from that of human
papillomaviruses (viruses suspected to occur more
strongly in the background of OSCC), in which the car-
riage of human papillomaviruses on the apparently heal-
thymucosa of patients with virus-free tumourswas almost
the same as that in the controls (Szarka et al., in press11 ). In
brief, including the healthy mucosa of the patients in the
analysis revealed that EBV is not associated with the
lesion itself, but rather with OSCC as a disease.
The aetiological role of EBV in OSCC cannot entirely
be ruled out, as it is possible that it contributes to car-
cinogenesis, but12 only in a minority of the tumours, an
eﬀect that is not demonstrable as a result of being
obscured by the other more important eﬀects in the rel-
atively small populations used in most studies, including
the present study.13 However, the uniform lack of LMP-1
expression in the OSCC tumour cells, found in this study
as well as in previous studies in European patients (7),
represents another strong argument against the
aetiological role.
The high prevalence of EBV DNA in the tumour tissue
may be a result of inﬁltrating B lymphocytes and
macrophages infected with EBV and/or to higher
susceptibility of the tumour keratinocytes to EBV
infection caused by an altered immunological environ-
ment arising from the presence of the tumour (14). These
factors may, similarly, also increase the prevalence of
EBV in the healthy mucosa.
This assumption is supported by the prevalence data in
the potentially malignant lesions. In our data set,
patients with OLP and OSCC, but not with OL, carried
signiﬁcantly more EBV DNA than controls. Similar data
have been reported by Sand et al. (8). The diﬀerence
between OLP and OL can conveniently be explained by
the distinct pathomechanisms of the two diseases: OLP is
a disease with a primarily autoimmune pathomechanism
(20–22); and OL develops mostly on the background of
chronic mechanical or chemical irritation (23, 24). It is
tempting to speculate that the autoimmune processes
lead to an oral environment more favourable for EBV
re-activation and shedding, probably provoked and
maintained by the altered cytokine proﬁle (25). As
immunological changes are present both in OLP and in
OSCC, but are not characteristic in OL, this similarity
may be the basis of the higher prevalence in both OSCC
and OLP.
Data provided in the literature suggest that the role of
EBV in OSCC may vary according to geographical
regions, for example, in some populations (e.g. Japanese,
Chinese, North Africans), EBV may play a role in OSCC
(9, 10, 26); by contrast, in North American and North
European populations the role is less probable (14, 15).
Our data suggest that the Hungarian population belongs
to the latter group.
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Notably, those populations in which the aetiological
role of EBV in OSCC is more probable are generally the
same, where EBV-associated nasopharyngeal carcinoma
is prevalent (6, 27). This suggests that the genetic and/or
habitual factors aiding EBV in the pathogenesis of
nasopharyngeal carcinoma may similarly provide an
opportunity for EBV to contribute to the development of
OSCC in these populations.
Our data draw attention to the fact that high preva-
lences of EBV in oral lesions compared with controls do
not always indicate a true association, and inclusion of
the apparently healthy mucosa/tissues into similar stud-
ies aid in the correct interpretation of the data.
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